Quantcast

Latest Prostate cancer Stories

2014-09-11 16:28:16

QUEBEC CITY, Sept. 11, 2014 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation") today reported financial and operational results for the third quarter 2014 ended July 31, 2014. The Corporation announced a net loss of $504,105 or $0.01 per share for this quarter compared with a loss of $595,262 or $0.01 per share for the same period last year. During the third quarter ended July 31, 2014, total revenues decreased by 19% compared with the same quarter of 2013, due to...

2014-09-11 16:27:19

BOSTON, Sept. 11, 2014 /PRNewswire-USNewswire/ -- The Prostate Health Education Network (PHEN) announced today that it will host its "Tenth Annual African American Prostate Cancer Disparity Summit," in the Russell Senate Office Building, on Capitol Hill, and at the Washington Convention Center, from September 25 - 26, 2014. The Summit will focus on African American men's most pressing prostate cancer issues, including: -- Clarity on the Prostate Specific Antigen (PSA) Test and the...

2014-09-11 12:27:33

SANTA MONICA, Calif., Sept. 11, 2014 /PRNewswire-USNewswire/ -- The Prostate Cancer Foundation (PCF) has awarded 27 new Young Investigator Awards selected from 16 countries to advance new drug discovery, immunotherapy, nutritional sciences, and diagnostics for precision medicine. Young Investigator (YI) Awards stand out among PCF's prestigious research programs, and serve to jumpstart the research careers of recent MDs and PhDs. These 3-year awards are game-changing investments that...

2014-09-11 08:28:17

Hosting an educational symposium highlighting treatment advances using the Company's high-dose rate electronic brachytherapy system NASHUA, N.H. and SAN FRANCISCO, Sept. 11, 2014 /PRNewswire/ -- (Booth #1938) -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will debut the Company's latest technological advances and present updates on clinical data and patient...

2014-09-10 16:26:51

Approval based on improved overall survival, delayed time to radiographic progression and an overall positive benefit-risk profile TOKYO and SAN FRANCISCO, Sept. 10, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI(®) (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). This new approved...

2014-09-09 08:31:59

SAN ANTONIO, Sept. 9, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs." The patent covers the composition of a specific prodrug activated by Prostate Specific Antigen (PSA) that is designed to deliver a thapsigargin derivative selectively to prostate cancers. PSA is an enzyme...

2014-09-09 08:31:36

Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif., Sept. 9, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX(®) in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, September 26 - 30. Included in the program is the first presentation of strongly positive results from an...

2014-09-08 12:28:32

OWINGS MILLS, Md., Sept. 8, 2014 /PRNewswire-USNewswire/ -- Chesapeake Urology, the largest urology practice in the mid-Atlantic and one of the leading urology groups in the nation, is sponsoring its 8(th) Annual ZERO Prostate Cancer Challenge/Baltimore (ZPCC) on Sunday, September 14, 2014 during Prostate Cancer Awareness Month. The event will be held at Towson University's Johnny Unitas Stadium in Towson, MD. Dr. Sanford J. Siegel, President and CEO of Chesapeake Urology,...

2014-09-08 08:31:12

Patients also report significant impact on mood and career WASHINGTON, Sept. 8, 2014 /PRNewswire/ -- A recent survey conducted by ZERO - The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs) that support them. The majority (64 percent) of patients surveyed report that their prostate cancer diagnosis has a moderate to severe impact on their social and emotional wellbeing....

2014-09-08 08:31:01

BETHESDA, Md., Sept. 8, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, CEO, will present at 2:05 pm on Tuesday, September 9, 2014, in the Holmes I Salon at the Palace Hotel in New York as part of the Rodman & Renshaw 16(th) Annual Global Investment Conference. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related